Predicting Enhanced Cell Killing through PARP Inhibition
نویسندگان
چکیده
منابع مشابه
Predicting enhanced cell killing through PARP inhibition.
PARP inhibitors show promise as combination and single agents in cancer chemotherapy. Here, we evaluate results obtained with mouse fibroblasts and the common laboratory PARP inhibitor 4-amino-1,8-naphthalimide (4-AN) and analyze the potential for enhanced cytotoxicity following the combination of a DNA-damaging agent and a PARP inhibitor. Methylated DNA bases are repaired by the monofunctional...
متن کاملPARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells
High consumption of dietary flavonoids might contribute to a reduction of cancer risks. Quercetin and its glycosides have PARP inhibitory effects and can induce selective cytotoxicity in BRCA2-deficient cells by synthetic lethality. We hypothesized that common flavonoids in diet naringenin, hesperetin and their glycosides have a similar structure to quercetin, which might have comparable PARP i...
متن کاملSelectively killing transformed cells through proteasome inhibition
consistent with origin activation during the 1st pulse period; (2) Uni-directional forks—contain a track of 1st label with an adjacent track of 2nd label, consistent with individual growing forks; (3) Clustered replicons—contain intermingled and contiguous tracks of 1st and 2nd label, which must represent clustered replicons that engaged and completed synthesis during labelling. Because labelli...
متن کاملEnhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
Poly-ADP ribose polymerase (PARP) inhibitors have shown promise in the treatment of human malignancies characterized by deficiencies in the DNA damage repair proteins BRCA1 and BRCA2 and preclinical studies have demonstrated the potential effectiveness of PARP inhibitors in targeting ataxia-telangiectasia mutated (ATM)-deficient tumours. Here, we show that mantle cell lymphoma (MCL) cells defic...
متن کاملEnhanced dendritic cell development through long-term proteasome inhibition
Bortezomib (BTZ) is a reversible proteasome inhibitor. It affects NF-κB activity and has shown clinical efficacy in multiple myeloma. However, the same mechanisms through which it curtails malignant growth may compromise antitumor immunity. As dendritic cells (DC) play a vital role in the elicitation and maintenance of antitumor immunity, we studied the long-term effects of BTZ on human DC deve...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Cancer Research
سال: 2012
ISSN: 1541-7786,1557-3125
DOI: 10.1158/1541-7786.mcr-12-0512